Direct influence of C-terminally substituted amino acids in the Dmt-Tic pharmacophore on δ-opioid receptor selectivity and antagonism

Journal of Medicinal Chemistry

Volumn 47, Issue 16, 2004, Pages 4066-4071

  Balboni, Gianfranco ^a   Salvadori, Severo ^b   Guerrini, Remo ^b   Negri, Lucia ^c   Giannini, Elisa ^c   Bryant, Sharon D ^d   Jinsmaa, Yunden ^d   Lazarus, Lawrence H ^d  

^a UNIVERSITY OF CAGLIARI   (Italy)

^b UNIVERSITY OF FERRARA   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

^d NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DELTA OPIATE RECEPTOR; DELTA OPIATE RECEPTOR AGONIST; DELTA OPIATE RECEPTOR ANTAGONIST; DELTORPHIN; DELTORPHIN C; DERMORPHIN; ENKEPHALIN[2 DEXTRO ALANINE 4 METHYLPHENYLALANINE 5 GLYCINE]; ENKEPHALIN[2,5 DEXTRO PENICILLAMINE]; MU OPIATE RECEPTOR; PEPTIDE DERIVATIVE; UNCLASSIFIED DRUG;

AMINO ACID SUBSTITUTION; ANIMAL TISSUE; ARTICLE; CHIRALITY; CONCENTRATION RESPONSE; DRUG ANTAGONISM; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; GUINEA PIG; ILEUM; INTESTINE MUSCLE; MALE; MYENTERIC PLEXUS; NONHUMAN; PHARMACOPHORE; RECEPTOR AFFINITY; SMOOTH MUSCLE RELAXATION; STRUCTURE ACTIVITY RELATION;

AMINO ACID SUBSTITUTION; ANIMALS; BINDING, COMPETITIVE; BRAIN; DIPEPTIDES; ELECTRIC STIMULATION; GUINEA PIGS; MALE; MICE; MUSCLE CONTRACTION; MUSCLE, SMOOTH; RADIOLIGAND ASSAY; RATS; RECEPTORS, OPIOID, DELTA; RECEPTORS, OPIOID, MU; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; SYNAPTOSOMES; TETRAHYDROISOQUINOLINES; VAS DEFERENS;

EID: 3242811223     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm040033f     Document Type: Article

References (48)

1. 2, negative log of the molar concentration required to double the agonist concentration to achieve the original response; tBu, tert-butyl; TFA, trifluoroacetic acid; THA, tetra-hydofurane; Tic, 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid; TIP(P), H-Tyr-Tic-Phe-(Phe)-OH; TLC, thin-layer chromatography; Trt, trityl; WSC, 1-ethyl-3-(3′-dimethylaminopropyl)-carbodiimide-HCl.
2. Fundytus, M.; Schiller, P.; Shapiro, M.; Weltrowska, G.; Coderre, T. Attenuation of morphine tolerance and dependence with the highly selective δ-opioid receptor antagonist TIPP[ψ]. Eur. J. Pharmacol. 1995, 286, 105-108.
3. Menkens, K.; Bilsky, E.; Wild, K.; Portoghese, P. S.; Reid, L.; Porreca, F. Cocaine place preference is blocked by the δ-opioid receptor antagonist, naltrindole. Eur. J. Pharmacol. 1992, 219, 345-346.
4. Hill, K. G.; Kiefer, S. W. Naltrexone treatment increases the aversiveness of alcohol for outbred rats. Alcohol.: Clin. Exp. Res. 1997, 21, 637-641.
5. Stomberg, M. F.; Casale, L.; Volpicelli, L.; Volpicelli, J. R.; O'Brien, C. P. A comparison of the effects of the opioid antagonists naltrexone, naltrindole, and β-funaltrexamine on ethanol consumption in the rat. Alcohol 1998, 15, 281-289.
6. Bryant, S. D.; Jinsmaa, Y.; Salvadori, S.; Okada, Y.; Lazarus, L. H. Dmt and opioid peptides: a potent alliance. Biopolymers 2003, 71, 86-102.
7. Portoghese, P. The design of δ-selective opioid receptor antagonists. Farmaco 1993, 48, 243-251.
8. Farouz-Grant, F.; Portoghese, P. S. Pyrrolomorphinans as δ opioid receptor antagonists. The role of steric hindrance in conferring selectivity. J. Med. Chem. 1997, 40, 1977-1981.
9. Nagase, H.; Kawai, K.; Hayakawa, J.; Wakita, H.; Mizusuna, A.; Matsuura, H.; Tajima, C.; Takezawa, Y.; Endoh, T. Rational drug design and synthesis of a highly selective nonpeptide δ-opioid antagonist, (4aS*,12aR*)- 4a-(3-hydroxyphenyl)-2-methyl-1,2,3,4,4a,5,12a-ocatahydropyridol[3,4-b]acridine (TAN-67). Chem. Pharm. Bull. 1998, 46, 1695-1702.
10. Calderon, S. N.; Rothman, R. B.; Porreca, F.; Flippen-Anderson, J. L.; McNutt, R. W.; Xu, H.; Smith, L. E.; Bilsky, E. J.; Davis, P.; Rice, K. C. Probes for narcotic receptor mediated phenomena. 19. Synthesis of (+)-4-[(aR)-α-((2S,5R)-4allyl-2,5-dimethyl-1-piperazinyl)-3-methoxybenzyl] -N,N-diethylbenzamide (SNC 80): a highly selective, nonpeptide δ opioid receptor agonist. J. Med. Chem. 1994, 37, 2125-2128.
11. Salvadori, S.; Attila, M.; Balboni, G.; Bianchi, C.; Bryant, S. D.; Crescenzi, O.; Guerrini, R.; Picone, D.; Tancredi, T.; Temussi, P. A.; Lazarus, L. H. δ Opioidmimetic antagonists: prototypes for designing a new generation of ultraselective opioid peptides. Mol. Med. 1995, 1, 678-689.
12. Temussi, P. A.; Salvadori, S.; Amodeo, P.; Bianchi, C.; Guerrini, R.; Tomatis, R.; Lazarus, L. H.; Tancredi, T. Selective opioid dipeptides. Biochem. Biophys. Res. Commun. 1994, 198, 933-939.
13. Schiller, P. W.; Nguyen, T. M.-D.; Weltrowska, G.; Wilkes, B. C.; Marsden, J.; Lemieux, C.; Chung, N. N. Differential stereochemical requirements of μ vs δ opioid receptors for ligand binding and signal transduction: development of a class of potent and highly δ-selective peptide antagonists. Proc. Natl. Acad. Sci. U.S.A. 1992, 89, 11871-11875.
14. Carpenter, K. A.; Weltrowska, C.; Wilkes, B. C.; Schmidt, R.; Schiller, P. W. Spontaneous diketopiperazine formation via end-to-end cyclization of a nonactivated linear tripeptide: an unusual chemical reaction. J. Am. Chem. Soc. 1994, 116, 8450-8458.
15. Capasso, S.; Sica, F.; Mazzarella, L.; Balboni, G.; Guerrini, R.; Salvadori, S. Acid catalysis in the formation of dioxopiperazines from peptides containing tetrahydroisoquinoline-3-carboxylic acid at position 2. Int. J. Pept. Protein Res. 1995, 45, 567-573.
16. Salvadori, S.; Balboni, G.; Guerrini, R.; Tomatis, R.; Bianchi, C.; Bryant, S. D.; Cooper, P. S.; Lazarus, L. H. Evolution of the Dmt-Tic pharmacophore: N-terminal methylated derivatives with extraordinary δ opioid antagonist activity. J. Med. Chem. 1997, 40, 3100-3108.
17. Balboni, G.; Salvadori, S.; Guerrini, R.; Bianchi, C.; Santagada, V.; Calliendo, G.; Bryant, S. D.; Lazarus, L. H. Opioid pseudo-peptides containing heteroaromatic or heteroaliphatic nuclei. Peptides 2000, 21, 1663-1671.
18. Santagada, V.; Balboni, G.; Caliendo, G.; Guerrini, R.; Salvadori, S.; Bianchi, C.; Bryant, S. D.; Lazarus, L. H. Assessment of substitution in the second pharmacophore of Dmt-Tic analogues. Bioorg. Med. Chem. Lett. 2000, 10, 2745-2748.
19. Balboni, G.; Guerrini, R.; Salvadori, S.; Bianchi, C.; Rizzi, D.; Bryant, S. D.; Lazarus, L. H. Evaluation of the Dmt-Tic pharmacophore: conversion of a potent δ-opioid receptor antagonist into a potent δ-agonist and ligands with mixed properties. J. Med. Chem. 2002, 45, 713-720.
20. Balboni, G.; Salvadori, S.; Guerrini, R.; Negri, L.; Giannini, E.; Yunden, J.; Bryant, S. D.; Lazarus, L. H. New potent δ-opioid agonists based on the Dmt-Tic pharmacophore. J. Med. Chem. 2002, 45, 5556-5563.
21. (a) Lazarus, L. H.; Salvadori, S.; Santagada, V.; Tomatis, R.; Wilson, W. E. Function of negative charge in the "address domain" of deltorphins. J. Med. Chem. 1991, 34, 1350-1359.
22. (b) Salvadori, S.; Bianchi, C.; Lazarus, L. H.; Scaranari, V.; Attila, M.; Tomatis, R. Para-substituted Phe3 deltorphin analogues: enhanced selectivity of halogenated derivatives for δ opioid receptor sites. J. Med. Chem. 1992, 35, 4651-4657.
23. Salvadori, S.; Guerrini, R.; Balboni, G.; Bianchi, C.; Bryant, S. D.; Cooper, P. S.; Lazarus, L. H. Further studies on the Dmt-Tic pharmacophore: Hydrophobic substituents at the C-terminus endows δ antagonists to manifest μ agonism or μ antagonism. J. Med. Chem. 1999, 42, 5010-5019.
24. Bryant, S. D.; George, C.; Flippen-Anderson, J.; Salvadori, S.; Balboni, G.; Guerrini, R.; Lazarus, L. H. Solid-state structure of analogues containing the Dmt-Tic pharmacophore. J. Med. Chem. 2002, 45, 5506-5513.
25. Schiller, P. W.; Nguyen, T. M.-D.; Weltrowska, G.; Wilkes, B. C.; Marsden, B. J.; Schmidt, R.; Lemieux, C.; Chung, N. N. TIPP opioid peptides: development of extraordinarily potent and selective δ antagonists and observation of astonishing structure-intrinsic activity relationships. Peptides: Chemistry and Biology; ESCOM: Leiden, The Netherlands, 1994; pp 483-486.
26. Kumar, V.; Murray, T. F.; Aldrich, J. V. Extended TIP(P) analogues as precursors for labelled δ-opioid receptor ligands. J. Med. Chem. 2000, 43, 5050-5054.
27. 1]deltorphin B. Eur. J. Pharmacol. 1996, 302, 37-42.
28. Guerrini, R.; Capasso, A.; Marastoni, A.; Bryant, S. D.; Cooper, P. S.; Lazarus, L. H.; Temussi, P. A.; Salvadori, S. Rational design of dynorphin A analogues with δ-receptor selectivity and antagonism for δ- and κ-receptors. Bioorg. Med. Chem. 1998, 6, 57-62.
29. Sasaki, Y.; Suto, T.; Ambo, A.; Ouchi, H.; Yamamoto, Y. Biological properties of opioid peptides replacing Tyr at position 1 by 2,6-dimethyl-Tyr. Chem. Pharm. Bull. 1999, 47, 1506-1507.
30. Schiller, P. W.; Nguyen, T. M.-D.; Berezowska, I.; Dupuis, S.; Weltrowska, G.; Chung, N. N.; Lemieux, C. Synthesis and in vitro opioid activity profiles of DALDA analogues. Eur. J. Med. Chem. 2000, 35, 895-901.
31. Schiller, P.; Nguyen, T.; Chung, N.; Lemieux, C. Dermorphin analogues carrying an increased positive net charge in their "message" domain display extremely high μ opioid receptor selectivity. J. Med. Chem. 1989, 32, 698-703.
32. Lazarus, L. H.; Salvadori, S.; Attila, M.; Grieco, P.; Bundy, D. M.; Wilson, W. E.; Tomatis, R. Interaction of deltorphin with opioid receptors: molecular determinants for affinity and selectivity. Peptides 1993, 14, 21-28.
33. Schiller, P. W.; Weltrowska, C.; Nguyen, T. M.-D.; Lemieux, C.; Chung, N. N.; Marsden, B. J.; Wilkes, B. C. Conformational restriction of the phenylalanine residue in a cyclic peptide analogue: effects of receptor selectivity and stereospecificity. J. Med. Chem. 1991, 34, 3125-3132.
34. 3-Substituted analogues of deltorphin C. Spatial conformation and topography of the aromatic ring in peptide recognition by δ opioid receptors. J. Med. Chem. 1993, 36, 3748-3756.
35. Capasso, A.; Amodeo, P.; Balboni, G.; Guerrini, R.; Lazarus, L. H.; Temussi, P. A.; Salvadori, S. Design of μ selective opioid dipeptide antagonists. FEBS Lett. 1997, 417, 141-144.
36. (a) Bryant, S. D.; Salvadori, S.; Attila, M.; Lazarus, L. H. Topographical conformations of the deltorphins predicate δ opioid receptor affinity. J. Am. Chem. Soc. 1993, 115, 8503-8504.
37. 4 in deltorphin A for high δ opioid receptor selectivity. Amino Acids 1994, 7, 291-304.
38. Okada, Y.; Tsuda, Y.; Fujita, Y.; Yokoi, T.; Sasaki, Y.; Ambo, A.; Konishi, R.; Nagata, M.; Salvadori, S.; Yunden, J.; Bryant, S. D.; Lazarus, L. H. Unique synthetic μ-opioid receptor agonists with central- and systemic-mediated analgesia. J. Med. Chem. 2003, 46, 3201-3209.
39. Berezowska, I.; Chung, N. N.; Lemieux, C.; Zelent, B.; Szeto, H. H.; Schiller, P. W. Highly potent fluorescent analogues of the opioid peptide Dmt(1) DALDA. Peptides 2003, 24, 1195-1200.
40. Atherton, E.; Sheppard, R. C. Solid Phase Peptide Synthesis: A Practical Approach; IRL Press: Oxford, U.K., 1989.
41. Dygos, J. H.; Yonan, E. E.; Scaros, M. G.; Goodmonson, O. J.; Getman, D. P.; Periana, R. A.; Beck, G. R. A convenient asymmetric synthesis of the unnatural amino acid 2,6-dimethyl-L-tyrosine. Synthesis 1992, 8, 741-743.
42. Sieber, P. An improved method for anchoring of 9-fluorenyl- methoxycarbonyl-amino acids to 4-alkoxybenzyl alcohol resins. Tetrahedron Lett. 1987, 28, 6147-6150.
43. Carpino, L. A. 1-Hydroxy-7-azabenzotriazole. An efficient peptide coupling additive. J. Am. Chem. Soc. 1993, 115, 4397-4398.
44. Balboni, G.; Salvadori, S.; Guerrini, R.; Negri, L.; Giannini, E.; Bryant, S. D.; Jinsmaa, Y.; Lazarus, L. H. Synthesis and opioid activity of N,N-dimethyl-Dmt-Tic analogues: acquisition of potent δ antagonism. Bioorg. Med. Chem. 2003, 11, 5435-5441.
45. Lazarus, L. H.; Wilson, W. E.; de Castiglione, R.; Guglietta, A. Dermorphin gene sequence peptide with high affinity and selectivity for δ-opioid receptors. J. Biol. Chem. 1989, 264, 3047-3050.
46. 50) of an enzymatic reaction. Biochem. Pharmacol. 1973, 22, 3099-3108.
47. Melchiorri, P.; Negri, L.; Flaconieri-Erspamer, G.; Severini, C.; Corsi, R.; Soaje, M.; Erspamer, V.; Barra, D. Structure-activity relationships of the δ-opioid-selective agonists, deltorphins. Eur. J. Pharmacol. 1991, 195, 201-207.
48. Tallarida, R. J.; Murray, R. B. Manual of Pharmacological Calculation, 2nd ed.; Springer-Verlag: New York, 1986.